All our findings suggest that PLAA acts as a tumor suppressor in ovarian cancer metastasis, and PLAA may have a potential to be clinically used as a biomarker associated with patient prognosis and a therapeutic target in metastatic ovarian cancer. This evidence concerns the gene PLAA and ovarian carcinoma.